Department of Biomedicine, University of Bergen, Jonas Lies vei 91, 5009, Bergen, Norway.
J Neurooncol. 2014 Jan;116(1):1-9. doi: 10.1007/s11060-013-1265-5. Epub 2013 Oct 2.
Natural killer (NK) cells are lymphocytes that play an important role in anti-tumour immunity. Their potential against brain cancer has been demonstrated in vitro and in vivo, both as a direct anti-tumour agent and in experimental therapies stimulating endogenous NK cell cytotoxicity. However, the clinical translation of these promising results requires detailed knowledge about the immune status of brain tumour patients, with focus on the NK cell population. In this report, we provide an overview of the studies investigating NK cell infiltration into the tumour, emphasizing the need of revision of the methodologies and further research in this field. We also discuss the potential of using autologous or allogeneic NK cells as effector cells in cellular therapy against brain cancer and developing immunotherapies stimulating endogenous NK cell-mediated anti-tumour response, such as blocking inhibitory killer immunoglobulin-like receptors. Combination of NK cell adoptive transfer with targeted therapies, such as anti-EGFR therapeutic antibody (CetuximAb) could also be a potent strategy.
自然杀伤 (NK) 细胞是淋巴细胞的一种,在抗肿瘤免疫中发挥着重要作用。它们在体外和体内对脑肿瘤的潜在作用已得到证实,既可作为直接抗肿瘤药物,也可作为刺激内源性 NK 细胞细胞毒性的实验治疗方法。然而,这些有前途的结果要在临床转化,就需要详细了解脑肿瘤患者的免疫状态,重点关注 NK 细胞群体。在本报告中,我们对研究 NK 细胞浸润肿瘤的文献进行了综述,强调了需要修订该领域的方法学并进一步研究。我们还讨论了使用自体或同种异体 NK 细胞作为细胞疗法对抗脑癌的效应细胞的潜力,并开发刺激内源性 NK 细胞介导的抗肿瘤反应的免疫疗法,例如阻断抑制性杀伤免疫球蛋白样受体。将 NK 细胞过继转移与靶向治疗(如抗 EGFR 治疗性抗体 [西妥昔单抗])相结合,也可能是一种有效的策略。